Actelion's Tracleer receives EU approval for paediatric PAH
This article was originally published in Scrip
Executive Summary
EU regulatory authorities have extended Acetelion's Tracleer (bosentan) licence to include pulmonary arterial hypertension (PAH) in children aged two years and older. This marks the first paediatric PAH treatment to be approved worldwide, says the company.